STAT News

STAT+: Pharmalittle: We’re reading about concerns over a rare disease drug, pharma payments to docs, and more

Patient advocates and some experts are expressing growing alarm over the perceived risks of a Neurocrine Biosciences rare disease drug

By STAT News

1 min read
STAT+: Pharmalittle: We’re reading about concerns over a rare disease drug, pharma payments to docs, and more
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights